Posts Tagged: Pharmaceutical


During the last hearing of the House Judiciary Committee there was an attempt to insert language via amendment that would make it impossible for Kyle Bass and others to challenge pharmaceutical patents via post grant challenge at the Patent …

Continue Reading

To listen to the critics, one would believe that the Trans-Pacific Partnership (TPP) Trade Agreement marks the end of the world for global health, especially for the poor. They are, in a word, wrong. Admittedly, the TPP Agreement is …

Continue Reading

HHS is suing a defendant that merely wants to market a generic version of a drug that is used to treat patients with human immunodeficiency virus (HIV). Not only is the United States government a patent troll, but the …

Continue Reading

There’s been a lot of positive activity in recent months for Bristol-Myers Squibb of New York City. In early March, the U.S. Food and Drug Administration approved the use of BMS’s immunotherapy drug Opvido for the …

Continue Reading

The early months of 2015 have been interesting ones for the pharmaceutical industry, an incredibly valuable industry sector that comes under our focus from time to time here at IPWatchdog. The first quarter of this calendar year has seen a …

Continue Reading

Claiming to be the ''Pharmacy to the Developing World'', India argues that their lax intellectual property rights regime is critical to their ability to provide low-cost, quality generic drugs. They are wrong on two counts. First, India needs to …

Continue Reading

Cystic fibrosis creates a thick, sticky mucus that builds up in the airways, causing infections, and making it difficult to breathe. Chronic pain is a common problem for patients, which increases dramatically during the last 6 months of life. Those …

Continue Reading

Merck & Co. (NYSE: MRK), which is headquartered in Whitehouse Station, NJ, and also does business under the name Merck Sharp & Dohme MSD, is one of the world’s largest and most renowned pharmaceutical development companies. The company …

Continue Reading

Every once and a while we get a clear example of the gulf between those battling over important public policy issues and can understand why the public and policy makers are confused by resulting charges and counter charges. The …

Continue Reading

It is tough to overstate the connection between the development of vaccines and public health, however. Since the use of vaccinations was first introduced by English physician Edward Jenner in 1798, many devastating diseases have either been eradicated or targeted …

Continue Reading

It is nearly universally accepted (and for a reason) that the process from discovery to market is long and costly. Drugs to not invent themselves and there are significant costs associated with nearly 13 to 14 years awaiting approvals. But even …

Continue Reading

Patent applications recently published by the U.S. Patent and Trademark Office show that Pfizer’s recent development goals have focused on a broad spectrum of diseases and disorders... Treatments for a number of bacterial infections which can develop …

Continue Reading